Ctrl K
CLYM trades 63.5% below Wall Street's consensus target of $26.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CLYM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 9, 2026, Climb Bio, Inc. (CLYM) has a Wall Street consensus price target of $26.00, based on estimates from 6 covering analysts. With the stock currently trading at $15.90, this represents a potential upside of +63.5%. The company has a market capitalization of $910M.
Analyst price targets range from a low of $17.00 to a high of $40.00, representing a 88% spread in expectations. The median target of $25.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLYM trades at a trailing P/E of -18.1x. Analysts expect EPS to grow -4.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $8.2B | $39.57 | $40.00 | +1.1% | Buy | — | 23 |
 ARQTArcutis Biotherapeutics, Inc. | $3.1B | $24.39 | $38.00 | +55.8% | Buy | 51.3x | 12 |
 DAWNDay One Biopharmaceuticals, Inc. | $2.2B | $21.53 | $21.50 | -0.1% | Buy | — | 12 |
 KYMRKymera Therapeutics, Inc. | $9.6B | $116.47 | $132.82 | +14.0% | Buy | — | 27 |
 PRAXPraxis Precision Medicines, Inc. | $9.8B | $352.48 | $603.83 | +71.3% | Buy | — | 18 |
 RVMDRevolution Medicines, Inc. | $44.1B | $207.32 | $247.69 | +19.5% | Buy | — | 24 |
 ACADACADIA Pharmaceuticals Inc. | $4.7B | $27.58 | $33.83 | +22.7% | Buy | 45.0x | 37 |
 INVAInnoviva, Inc. | $1.6B | $21.34 | $38.00 | +78.1% | Buy | 8.6x | 10 |
 PTGXProtagonist Therapeutics, Inc. | $9.4B | $145.94 | $169.38 | +16.1% | Buy | 31.2x | 26 |
 TARSTarsus Pharmaceuticals, Inc. | $3.8B | $87.22 | $95.67 | +9.7% | Buy | — | 10 |
Quick answers to the most common questions about buying CLYM stock.
The consensus Wall Street price target for CLYM is $26, representing 63.5% upside from the current price of $15.9. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CLYM has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $26 implies 63.5% upside from current levels.
CLYM's current price is $15.9 with a consensus target of $26 (63.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for CLYM, while the most conservative target is $17. The consensus of $26 represents the median expectation. These targets typically reflect 12-month expectations.
CLYM is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLYM stock forecast based on 6 Wall Street analysts shows a consensus price target of $26, with estimates ranging from $17 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CLYM, with a "Buy" consensus rating and $26 price target (63.5% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLYM analyst price targets range from $17 to $40, a 88% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $26 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.